115 related articles for article (PubMed ID: 17851833)
1. Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients.
Pálka I; Ormándi K; Gaál S; Boda K; Kahán Z
Acta Oncol; 2007; 46(8):1178-83. PubMed ID: 17851833
[TBL] [Abstract][Full Text] [Related]
2. Mammographic casting-type calcifications is not a prognostic factor in unifocal small invasive breast cancer: a population-based retrospective cohort study.
Månsson E; Bergkvist L; Christenson G; Persson C; Wärnberg F
J Surg Oncol; 2009 Dec; 100(8):670-4. PubMed ID: 19771563
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancer.
Kelemen G; Uhercsák G; Ormándi K; Eller J; Thurzó L; Kahán Z
Oncology; 2010; 78(3-4):271-3. PubMed ID: 20523088
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for late relapse and death in patients with early breast cancer.
Grasic-Kuhar C; Bracko M; Zakotnik B
Neoplasma; 2008; 55(5):416-20. PubMed ID: 18665752
[TBL] [Abstract][Full Text] [Related]
5. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer.
Ejlertsen B; Jensen MB; Rank F; Rasmussen BB; Christiansen P; Kroman N; Kvistgaard ME; Overgaard M; Toftdahl DB; Mouridsen HT;
J Natl Cancer Inst; 2009 May; 101(10):729-35. PubMed ID: 19436035
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
7. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
8. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
9. The relationship of multifocality and tumor burden with various tumor characteristics and survival in early breast cancer.
Kelemen G; Farkas V; Debrah J; Ormandi K; Voros A; Kaizer L; Varga Z; Lazar G; Kahan Z
Neoplasma; 2012; 59(5):566-73. PubMed ID: 22668023
[TBL] [Abstract][Full Text] [Related]
10. Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma.
Tabar L; Tony Chen HH; Amy Yen MF; Tot T; Tung TH; Chen LS; Chiu YH; Duffy SW; Smith RA
Cancer; 2004 Oct; 101(8):1745-59. PubMed ID: 15386334
[TBL] [Abstract][Full Text] [Related]
11. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
12. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
Di Saverio S; Gutierrez J; Avisar E
Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
[TBL] [Abstract][Full Text] [Related]
13. [Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype].
Gerson R; Alban F; Villalobos A; Serrano A
Gac Med Mex; 2008; 144(1):27-34. PubMed ID: 18619055
[TBL] [Abstract][Full Text] [Related]
14. Interval breast cancers: prognostic features and survival by subtype and time since screening.
Porter GJ; Evans AJ; Burrell HC; Lee AH; Ellis IO; Chakrabarti J
J Med Screen; 2006; 13(3):115-22. PubMed ID: 17007651
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
16. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Cancer; 2009 Nov; 115(21):4917-23. PubMed ID: 19691094
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer.
Parikh RR; Housman D; Yang Q; Toppmeyer D; Wilson LD; Haffty BG
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1056-63. PubMed ID: 18676094
[TBL] [Abstract][Full Text] [Related]
18. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731
[TBL] [Abstract][Full Text] [Related]
20. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
